Trazenta: nā loiloi o ka maʻi diabetes, hoʻopili, ʻike a me nā contraindications

No ka hiku o ka makahiki, ʻike ʻia kahi lāʻau lapaʻau maikaʻi loa no ka mālamaʻana i ka maʻi maʻi ma ka mākeke, ka hoʻohana ʻana ia mea ʻaʻole e hoʻonui i nā maʻi o ka pūnaehana cardiovascular, nā ʻōpū a me ka puʻuwai, i ʻōlelo ai nā maʻi maʻi. "ʻO Trazhenta", kahi i kau ʻia ma ka blocker o ka enzyme dipeptidyl peptidase-4 linagliptin, e pili ana i nā mānoanoa hypoclycemic. Ke hopena nei ka hopena o ka lāʻau lapaʻau e hōʻemi i ka hoʻoneʻe ʻana o ka hormonal substant glucagon, me ka hoʻonui ʻana i ka hana o ka insulin. Hoʻomaopopo ʻia kēia papa o nā lāʻau lapaʻau e like me kekahi o nā mea i hoʻohiki maikaʻi loa ai no ka mālama ʻana i kahi maʻi pōpilikia - ʻo ke ʻano lua o ka maʻi maʻi.

He aha ka maʻi diabetes?

ʻO kēia kekahi kulekele o ka ʻoihana endocrine, ma muli o ka ulu ʻana o ka glucose i ke koko o kēlā kanaka, ʻoiai ke oki nei ke kino i ka kū i ka insulin. He hopena koʻikoʻi nā hopena o kēia maʻi - ʻaʻole i hāʻule nā kaʻina metabolic, pili ka moku, nā ʻāpana a me nā ʻōnaehana. ʻO kekahi o nā mea weliweli a me ka hoʻoweliweli, ʻo ka maʻi maʻi o ka ʻano lua. Ua kapa ʻia kēia maʻi he hoʻoweliweli maoli i loko o ke kanaka.

I waena o nā kumu o ka makeʻe o ka lehulehu ma nā makahiki he ʻelua i hala, ua hiki mua. ʻO ka mea nui e hoʻonāukiuki i ka hoʻomohala ʻana i ka maʻi ua manaʻo ʻia he hana ʻole o ka ʻōnaehana. Hoʻohana ʻia nā Antibodies i loko o ke kino e loaʻa ai ka hopena luku ma nā cell pancreatic. Ma muli o kēia, ua hoʻokaʻawale ka glucose i nā nui nui i ke koko, a loaʻa ka hopena maikaʻi ʻole o nā huaka a me nā ʻōnaehana. Ma muli o ke kaupaona ʻana, hoʻohana ke kino i nā momona i mea e lilo ai i kumu hoʻoneʻe, e alakaʻi i ka hoʻokumu nui ʻana o nā kino ketone, he mau mea huikala. Ma muli o kēia, pau ke ʻano o nā kaʻina āpau o ka metabola e kū nei i loko o ke kino.

No laila, he mea koʻikoʻi loa ia ke kiʻi i kahi maʻi i koho i ka pono kūpono a kau i nā lāʻau lapaʻau kiʻekiʻe kiʻekiʻe, no ka laʻana, "Trazhentu", nā loiloi o nā kauka a me nā mea maʻi e ʻike ʻia ma lalo nei. ʻO ka pōpilikia o ka maʻi maʻi maʻi no ka manawa lōʻihi ʻaʻole ia e hāʻawi i nā hōʻike kulekele, a me ka nānā ʻia o nā waiwai gula ka nui keu me ka manawa kūpono e ʻike ʻia ai i ke ʻano pale.

ʻO nā hopena o ka maʻi maʻi

Ke hana mau nei nā ʻepekema ʻepuni a i ka honua i ka noiʻi ʻana i ka ʻike ʻana i nā palapala hou e hana ai i ka lāʻau lapaʻau e hiki ai ke lanakila i kahi maʻi weliweli. Ma 2012, ua hoʻopaʻa inoa ʻia kahi lāʻau lapaʻau kaʻawale i ko mākou ʻāina, ka mea maʻamau ʻaʻole ia e hoʻopiʻi i nā hopena a ʻae maikaʻi ʻia e nā maʻi. Eia kekahi, ʻae ʻia e ʻae i ke kanaka me ka maʻi hula a me ka maʻi hepatic - e like me ka mea i kākau ʻia ma nā loiloi o "Trazhent".

ʻO ka pōʻino weliweli kēia o nā hoʻopiʻi ʻana i ka maʻi maʻi:

ka emi ʻana o ke aniani a i kona pau ʻana,
ka hāʻule ʻole o ka hana ʻana o nā kuhi,
maʻi vascular a me ka puʻuwai - myocardial infarction, atherosclerosis, ischemic heart heart,
nā wāwae wāwae - nā hana maʻamau-purulent-necrotic, nā ʻōpio ulcerative,
ke ʻano o nā ʻōpala ma ka dermis,
huʻi ʻeha manu,
neuropathy, ka mea i hōʻike ʻia e nā mea hoʻokalakupua, peeling a me ka hoʻemi ʻana o ke ʻano o ka ʻili o ka ʻili,
koma
ka hana hewa ʻana i nā hana o nā ʻoi loa.

"Trazhenta": wehewehe, hoʻonohonoho

Hōʻā ʻia kahi lāʻau lapaʻau ma ka palapala dosage formage. ʻO nā papa papa biconvex me nā kihi beveled me ka ʻulaʻula ulaula. Ma kekahi ʻaoʻao kahi hōʻailona o ka mea hana, hōʻike ʻia i ke ʻano o ke kahakaha, ma ka ʻaoʻao - ʻo ka alphanumeric design D5.

ʻO ka mea waiwai he linagliptin, ma muli o kāna hana kūpono no ka pākahi hoʻokahi, lawa ka ʻelima milligrams. ʻO kēia māhele, e hoʻonui ana i ka hana o ka insulin, hōʻemi i ka syntagon syntagon. Loaʻa ka hopena i hoʻokahi haneri a me iwakālua mau minuke ma hope o ka hoʻokele ʻana - ma hope o kēia manawa ke nānā ʻia kona kiʻekiʻe nui o ke koko. Mea pono kūpono no ka hoʻokumu ʻana i nā papa:

konekena stearate,
pregelatinized a me nā māka palaoa,
manikiit he mannitol,
ʻO ka copovidone kahi mea komo.

ʻO ka pūpū ka hana o ka hypromellose, talc, ka ʻulaʻula (hao oxide), macrogol, titanium dioxide.

Nā hiʻohiʻona o ka lāʻau lapaʻau

Wahi a nā kauka, "Trazhenta" ma ka hoʻomaʻamaʻa lāʻau lapaʻau ua hōʻoia i kona pono i ka mālama ʻana o ka lua o ka maʻi mellitus lua o nā ʻāina he kanalima o ka honua, ʻo Russia hoʻi. Ua mālama ʻia nā haʻawina ma nā ʻāina he iwakāluakūmālua i mau tausani o nā mea maʻi me ka lua o ka maʻi maʻi i hana i ka hoʻāʻo ʻana i ka lāʻau.

Ma muli o ka mea i pau ka lāʻau mai ke kino o ke kanaka ma o ka ʻili o ke kuleana o ka gastrointestinal, a ʻaʻole ma o ka ʻōpū, ʻaʻole pono ka makee ʻana o ka make inā huakaʻi kā lākou hana. ʻO kēia kekahi o nāʻokoʻa nui ma waena o Trazenti a me nā mea hou antidiabetic. ʻO ka pōmaikaʻi like penei: ʻaʻohe maʻi o ka mea maʻi i ka lawe ʻana i nā papa, i hui pū ʻia me Metformin, a me monotherapy.

E pili ana i nā mea hana o ka lāʻau lapaʻau

ʻO ka hana ʻana o nā papa Trazhenta, nā loiloi e manuahi ʻia ana, e lawe ʻia ana e ʻelua mau lāʻau lapaʻau.

"Eli Lilly" - no 85 mau makahiki ua lilo kekahi o nā alakaʻi o ka honua i ke ʻano o nā hoʻoholo i manaʻo ʻia e kākoʻo ana i nā mea maʻi me ka maʻi o ka maʻi maʻi. Ke hoʻomau nei ka ʻoihana i kāna awelika me ka hoʻohana ʻana i ka noiʻi hou loa.
"Beringer Ingelheim" - alakaʻi i kāna mōʻaukala mai ka makahiki 1885. Ke hana nei ʻo ia i nā noiʻi, hoʻomohala ʻana, hana ʻana, me ka kūʻai ʻana i nā lāʻau lapaʻau. ʻO kēia ʻoihana he mea hoʻokahi o nā alakaʻi he iwakālua o ka honua i ka lāʻau o nā lāʻau lapaʻau.

I ka makahiki mua o 2011, ua hoʻopaʻa inoa ʻelua mau hui i ka ʻikepili ma ke ʻano o ka maʻi maʻi o ka maʻi maʻi, no ka mea ua hoʻokō nui ʻia ka holomua nui o ka mālama ʻana i nā maʻi ʻino. ʻO ke kumu o ka hoʻopili ʻana ke aʻo ʻana i kahi hui hou o nā lāʻau ʻehā i ʻāpana o nā lāʻau lapaʻau i hoʻolālā ʻia e hoʻopau ai i nā hōʻailona o ka maʻi.

Nā hōʻailona no ka hoʻohana ʻana

Wahi a nā loiloi a me nā ʻōnaehana no ka hoʻohana ʻana, "Trazhenta" e noi ʻia no ka hoʻohana ʻana no ka mālama ʻana i ka lua o ka maʻi diabetes mellitus ʻelua me ka monotherapy a i hui pū ʻia me nā papa āpau hypoglycemic tablet, a me ka hoʻomākaukau o ka insulin. I ka hihia mua, ua kuhikuhi ʻia no:

contraindications e lawe aku ana i ka Metformin a pōʻino paha,
ka nele o ka mālama glycemic kūʻē i ke kua o ka hoʻonaʻauao kino a me ka ʻai kūikawā.

Me ka maikaʻi ʻole o ka monotherapy me nā lāʻau lapaʻau e hiki mai ana, a me ke kōkua o ka ʻai ʻana a me ka hoʻomaʻamaʻa ʻana, hōʻike ʻia ka mālama paʻakikī.

Me nā derivatives sulfonylurea, Metformin, thiazolidinedione.
Me ka insulin a me Metformin, pioglitazone, sulfonylureas a me nā insulin.
Me nā metivatives Metformin a me nā konohuna sulfonylurea.

Nā Hoʻohui

Wahi a nā loiloi a me nā ʻōlelo aʻo, "Trazhent" ʻaʻole i ka lawe ʻia e kali nei ke kali ana ke pēpē a me ka wā e ʻai nei. Ma nā noi preclinical, ua ʻike ʻia ka waiwai ikaika (linagliptin) a me kāna mau metabolits i loko o ka waiū umauma. No laila, hikiʻole ke hoʻokaʻawale i kahi hopena maikaʻi loa i ka pūpū a me nā popo e pili ana i ka hoʻoulu ʻana. Inā hiki ʻole ke kāpae i ka lāʻau lapaʻau a kāpili iā ia me kahi like me ka mea like, hoʻoweliweli ka poʻe kauka i ka neʻe mai ka pilikino i ka hānai maoli.

Hoʻopili ʻia ka hoʻohana ʻana i nā papa i loko o kēia mau kūlana:

makahiki ʻewalu,
maʻi maʻamau ketoacidosis,
maʻi diabetes type 1
ka launa ʻana o kēlā me kēia mea e haku ʻia ai ka "Trazenti".

Ma nā loiloi o nā kauka, a ma ka ʻōlelo no ka hoʻohana ʻana i kēia lāʻau lapaʻau, aia kahi ʻike e pono e hoʻohana me ka akahele no nā poʻe ʻoi aku he kanawalu makahiki a ʻo ia e lawe nei me ka insulin a (a) i nā lāʻau lapaʻau i hoʻokumu ʻia o kaonyony. ʻAʻole i lawe ʻia nā haʻawina e pili ana i ka hopena o ka lāʻau lapaʻau ma ka hiki ke lawe i nā mīkini a me nā kaʻa. Eia nō naʻe, ma muli o ka hiki ʻana o ka hypoglycemia, inā no ka loaʻa ʻana o ka lāʻau hoʻohui lāʻau, pono e hoʻomaʻamaʻa. Inā ʻike ʻia ka maʻi pancreatitis, pono e hoʻokuʻu ʻia ka lāʻau. I kēia hihia, e koho ke kauka i kahi lāʻau ʻē aʻe.

Nā ʻōlelo kikoʻī

He mea nui e hoʻomanaʻo no ka loaʻa ʻana o ka ketoacidosis o ke ʻano maʻi diabetes mellitus o 1, pāpā ʻia ʻo Trazenti. Ma nā loiloi maʻi maʻi, he ʻano maʻamau ka mea laha. Eia kekahi, ʻoi aku ka maikaʻi o ka hōʻeuʻeu o nā pathologies o ke ʻano o ka puʻuwai ulu i hoʻonui. ʻO nā mea ola me ka hōʻehaʻole o nā pepi a me nā puʻuwai e hiki palekana i ka lāʻau lapaʻau i loko o ka maʻi maʻamau, ʻaʻole pono kona hoʻoponopono.

I ka makahiki makahiki mai kanahiku a ʻewalu mau makahiki, hōʻike ke hoʻohana ʻana i ka linagliptin i nā hopena maikaʻi. Ua mālama ʻia kahi emi ʻana o ka nui:

kekipukapuka hemoglobin,
ʻO ke kaila plasma i ka ʻōpū ʻole.

Ke lawe nei i ka lāʻau lapaʻau e nā poʻe i hala i ka hōʻailona he kanawalukūmole e hana ʻia me ka makaʻala loa, no ka mea, ua palena loa ka ʻike lāʻau lapaʻau me kēia hui.

ʻO ka loli o ka hypoglycemia ka liʻiliʻi inā lawe wale i kahi o "Trazenta". Hoʻopiʻi ka loiloi hoʻomanawanui i kēia ʻoiaʻiʻo. Eia kekahi, i kā lākou ʻōlelo, ʻike lākou i ka hui pū ʻana me nā lāʻau ʻē aʻe no ka maʻi maʻi, hiki ʻole ke hoʻomohala ʻia ka ulu ʻana o ka glycemia. I kēia mau hihia, inā pono, hiki i ke kauka ke hōʻemi i ka nui o ka insulin a me nā derivatives o sulfonylurea. ʻAʻole hoʻonui ka ʻaha "Trazhenty" i ka hopena o ka hōʻeha ʻana o ka puʻuwai a i ʻole ka hōʻeha ʻana, he mea nui ia i ka wā e lawe ai i ka wā ʻelemakule.

Nā hopena maikaʻiʻole

Nui nā lāʻau lapaʻau i hoʻohana ʻia e mālama ai i ka maʻi mellitus i mea e hiki ai i kahi kūlana pathological ke emi nei ka nui o ka glucose i ke koko. "Trazhenta", i loko o nā loiloi o ka mea i ʻōlelo ʻia me ka lawe ʻole ʻana ʻaʻole ia i kumu i ka hypoglycemia, he mea hoʻoneʻe i ka rula. Hoʻomaopopo ʻia kēia mea he pono nui ma mua o nā papa ʻē aʻe o nā mea pena hypoglycemic. ʻO nā hopena piliʻino e hiki ke hele i ka manawa o ka therapy "Trazentoy", i kēia mea:

lōkohu
waʻa hoʻohālikelike
nasopharyngitis,
haaheo
hoʻonui i ka plasma amylase,
ʻohiʻala
me nā mea ʻē aʻe.

I kahi hihia o kahi overdose, hōʻike ʻia nā hana maʻamau e kāohi i kahi lāʻau kū ʻole mai ka wahi o ka puna a me ka mālama maʻi.

"Trazhenta": nā loiloi o ka maʻi maʻi a me nā kauka lapaʻau

Ua hōʻoia pinepine ʻia ka hana kiʻekiʻe o ka lāʻau lapaʻau e ka lāʻau lapaʻau a me nā haʻawina hoʻokolohua. Hoʻokomo ka Endocrinologists i kā lākou ʻōlelo i ka hoʻohana ʻana iā ia ma ka hui ʻana a i ʻole ʻo ia he lapaʻau mua ma mua. Inā makemake kekahi o ka kanaka i ka hypoglycemia, ka mea e hoʻonāukiuki i nā meaʻai a me nā hana kūlohelohe, pono e kuhikuhi iā "Trazent" ma kahi o sulfonylurea derivatives. ʻAʻole hiki i nā wā a pau e loiloi i ka maikaʻi o ka lāʻau lapaʻau inā lawe ʻia i loko o nā hui hoʻohui, akā i ka laulā ke kūleʻa ka hopena, ʻike ʻia hoʻi e nā mea maʻi. Aia nā loiloi e pili ana i ka lāʻau "Trazhenta" i ke aʻo ʻia no ka momona a me ke kūʻē o ka insulin.

ʻO ka pōmaikaʻi o kēia mau papa antidiabetic ʻaʻole lākou i hāʻawi i ka loaʻa ʻana o ka paona ʻana, ʻaʻole i hoʻonāukiuki i ka hoʻomohala ʻana o ka hypoglycemia, ʻaʻole hoʻi hoʻonāukiuki i nā pilikia o ka lolo. Ua hoʻonui ʻo Trazhenta i ka palekana, he mea nui loa ia no ka maʻi maʻi. No laila, aia kekahi helu nui o nā loiloi kūpono e pili ana i kēia mea hana maʻalahi. Ma waena o nā minuke ke kahakaha nei ke kumukūʻai kiʻekiʻe a me nā intolerance pilikino.

Nā huahana huakaʻi "Trazhenty"

ʻO nā loiloi i waiho ʻia e nā mea maʻi e lawe ana i kēia lāʻau lapaʻau ka mea maikaʻi loa. Eia nō naʻe, no kekahi poʻe, ma muli o ka hypersensitivity a i ʻole intolerance, ʻōlelo aku nā kauka i nā lāʻau like ʻole. E pili ana kēia:

"Sitagliptin", "Januvia" - lawe nā mea maʻi i kēia hōʻokoʻa no ka hoʻomaʻamaʻa ʻana, ka meaʻai, ka hoʻomaʻamaʻa ʻana i ka mālama ʻana i ke kūlana glycemic, ʻo ka hoʻohui ʻana ka mea hoʻohana i ka lāʻau hoʻohui.
"Alogliptin", "Vipidia" - ke hōʻike pinepine nei kēia lāʻau lapaʻau i ka loaʻa ʻole o ka hopena o ka meaʻai meaʻai, ka hana kino a me ka monotherapy,
"Saksagliptin" - ua hana ʻia ma lalo o ka inoa inoa kālepa ʻo "Ongliza" no ka mālama ʻana i ka lua o ke ʻano maʻi maʻi mellitus, hoʻohana ʻia nō i ka monotherapy a me nā lāʻau lapaʻau ʻē aʻe a me inulin.

Ke lawe ʻia nei ke koho ʻana i kahi aniani e ka mālama ʻana i ka endocrinologist, ʻaʻole pāpā ʻia ka loli kūʻokoʻa.

ʻO nā mea maʻi me ka maikaʻi ʻole o ka pūpū

"Maikaʻi maikaʻi loa nā lāʻau lapaʻau" - ʻo ia mau huaʻōlelo e hoʻomaka i nā loiloi hopena e pili ana i ka "Trazhent". ʻO ka hopohopo koʻikoʻi ke lawe nei i nā lāʻau antidiabetic i ʻike pinepine ʻia e nā poʻe me ka hana hewa ʻana o nā pūpū, ʻoi aku hoʻi nā mea e kau nei i ka hemodialysis. I ka hiki ʻana mai o kēia lāʻau lapaʻau i ka ʻoihana kūʻai lapaʻau, hoʻomaikaʻi ʻia nā mea maʻi me nā ʻōiwi noi, ʻoiai ke kumukūʻai kiʻekiʻe.

Ma muli o ka hana ʻokoʻa a ka lāʻau lapaʻau, hoʻemi nui nā kumu glucose i ka wā e lawe nei i ka lāʻau lapaʻau i hoʻokahi manawa wale i ka lā ma kahi lāʻau lapaʻau o ʻelima mau milligrams. A he mea ʻole ia i ka manawa e lawe i nā papa. Hoʻopili wikiwiki ʻia ka lāʻau lapaʻau ma hope o ka komo ʻana i ka hana kūwili ʻana, ʻike ʻia ka lōʻihi o ke koʻikoʻi ma hope o hoʻokahi a me nā hapalua a ʻelua paha mau hola ma hope o ka lawelawe ʻana. Hoʻokuʻu ʻia ʻo ia i nā feces, ʻo ia hoʻi, ʻaʻole pili nā kuli a me ke ake i kēia hana.

Hoʻohālikelike

Wahi a nā loiloi maʻi maʻi, hiki ke lawe ʻia ʻo Trazhent i kēlā me kēia manawa kūpono, me ka ʻike ʻole i ka meaʻai a hoʻokahi wale nō hoʻokahi lā i ka lā, i manaʻo ʻia he hui nui. ʻO ka mea e hoʻomanaʻo ai: ʻaʻole hiki iā ʻoe ke lawe i ʻelua kope ʻelua i ka lā hoʻokahi. I ka hui huiʻana, ʻaʻole i loli ka hapa o "Trazhenty". Eia kekahi, ʻaʻole pono kēlā hoʻoponopono ʻana i ka pilikia o nā pilikia. Hoʻomaʻamaʻa maikaʻi nā papa. "Trazhenta", nā loiloi o ka hoihoi loa, i loaʻa i kahi mea koʻikoʻi kūʻokoʻa me ka hana kiʻekiʻe. ʻAʻole mea nui he mea ʻoi loa ka hoʻokomo ʻia o ka lāʻau lapaʻau ma ka papa inoa o nā lāʻau lapaʻau i hōʻole ʻia i loko o nā lāʻau lapaʻau no nā papa lāʻau manu ʻole.

Trazhenta - keʻano a me ka palapala hoʻohālikelike

Hoʻopau, hana hoʻomoʻi ʻo BOEHRINGER INGELHEIM PHARMA (Kelemānia) a ʻo BOEHRINGER INGELHEIM ROXANE (USA) i ka lāʻau lapaʻau ma ke ʻano o nā convex round red tablets. Ma kekahi ʻaoʻao kahi hōʻailona kahakaha ʻo ka ʻoihana hana e pale ai i ka lāʻau lapaʻau mai nā fakes, ma kekahi - ʻo ka hōʻailona "D5".

Loaʻa kēlā me kēia me 5 mg o ka linagliptin hoʻolaʻa ikaika a me nā ʻano kaulike like ʻole e like me ke starch, dye, hypromellose, magnesium stearate, copovidone, macrogol.

ʻO kēlā me kēia alumini blister pākuhi a 7 a he 10 mau papa o ka lāʻau Trazhenta, ke kiʻi hiki ke ʻike ʻia i kēia ʻāpana. I loko o ka pahu e hiki ai iā lākou ke helu ʻē aʻe - mai ʻelua a ʻewalu papa. Inā loaʻa ka blister he 10 mau papa me nā papa, a laila ma loko o ka pahu i laila he 3 mau papa o ia mau mea.

Lapaʻau

ʻIke maoli ʻia nā ala o ka lāʻau lapaʻau ma muli o ka kaomi ʻana o ka hana a dipeptidyl peptidase (DPP-4). Hoʻopilikia kēia enzyme

ma luna o nā hormones HIP a me GLP-1, he kuleana koʻikoʻi ka mālama i ka kaulike o ka glucose. Hoʻonui ka mea hoʻonui i ka hana insulin, kōkua i ke kāohi glycemia, a pale i nā mea huna o glucagon. He manawa pōkole kā lākou hana; ma hope iho, neʻoki ʻo HIP a me GLP-1 i nā enzyme. Hoʻopili hou ʻia ʻo Trazhenta me DPP-4, ʻae kēia iā ʻoe e mālama i ke olakino o incretins a hoʻonui i ko lākou pae kūpono.

Hoʻolima ka ʻano o ka mana o Trazhenty i nā loina o ka hana a nā metala'ē aʻe - Januvius, Galvus, Ongliza. Hoʻohana ʻia ka HIP a me GLP-1 i ka wā i komo ai nā mea kanu i ke kino. ʻAʻole pili me ka maikaʻi o ka lāʻau lapaʻau me ka hoʻoulu ʻana o kā lākou hana, hoʻonui wale ʻia ka lāʻau i ka lōʻihi o ko lākou kūkā ʻana. Ma muli o ia mau ʻano, ʻo Trazhenta, e like me ka incretinomimetics ʻē aʻe, ʻaʻole ia i hoʻonāukiuki i ka hoʻomohala ʻana o ka hypoglycemia, a he hopena maikaʻi kēia no nā papa o nā lāʻau lapaʻau hypoglycemic.

Inā ʻaʻole nui paha ka nui o ke kō, ua kōkua nā hua nui i ka hoʻonui ʻana i ka hana o ka insulin endogenous e nā β-cell. ʻO ka hormon GLP-1, he mau helu koʻikoʻi ia o nā mea hiki ke hoʻohālikelike i ka GUI, poloka i ka hoʻopili ʻana o ka glucagon i nā pona o ka ate. Ke kōkua nei kēia mau hana āpau i ka mālama pono i ka glycemia ma ka pae kūpono - e hōʻemi ai i ka hemoglobin glycosylated, ka wikiwiki i ke kō a me ka hoʻokaʻa glucose ma hope o ka hana ʻana me ka pālua o ʻelua hola. I ka lāʻau paʻakikī me ka hoʻomākaukau me metformin a me ka hoʻomākaukau ʻana o ka sulfonylurea, e hoʻomaikaʻi ana nā hiʻohiʻona glycemic me ka loaʻa ʻole o ka waiwai koʻikoʻi.

Lapaʻau lāʻau

Ma hope o ke komo ʻana i ka hāwele hana ʻana, e hopu koke ka lāʻau iā Cmax ma hope o hoʻokahi hola a me ka hapa. Ke emi nei ka neʻe ʻana i nā lua ʻelua.

ʻAʻole paʻa ka hoʻohana ʻana o nā papa me ka meaʻai a i ʻole ma kahi ma ka pharmacokinetics o ka lāʻau lapaʻau. ʻO ka bioavailability o ka lāʻau hiki ke 30%. Ka pālahalaha haʻahaʻa helu liʻiliʻi, 5% excreted e nā keiki, 85% hoʻopiʻi ʻia me nā feces. ʻAʻole koi kahi ʻano o ke aʻalopona e hoʻoneʻe i ka lāʻau lapaʻau a i ʻole ka loli o ka hopena. ʻAʻole i aʻo ʻia nā hiʻohiʻona o nā pharmacokinetics i ke kamaliʻi.

ʻO wai ka lāʻau lapaʻau no

Ua kuhikuhi ʻia ʻo Trazent ma ke ʻano o ka lāʻau lapaʻau mua a i ʻole me ka hoʻohui ʻana me nā lāʻau lapaʻau haʻahaʻa.

Monotherapy. Inā hiki ʻole i ka mea maʻi hakahaka i nā lāʻau lapaʻau o ka papa o nā bigudins e like me ka metformin (no ka laʻana, me nā ala renal a ʻole intolerance pilikino i kāna mau mea), a me nā loli o ke ola, ʻaʻole ia e lawe mai i nā hopena i makemake ʻia.
ʻElua papa ʻāpana. Hoʻonohonoho ʻia ka Trazent me ka hoʻomākaukau ʻana o ka sulfonylurea, metformin, thiazolidinediones. Inā maʻi ka maʻa i ka insulin, e hoʻohui paha i ka incretinomimetic.
Nā koho ʻekolu-wae. Inā ʻaʻole maikaʻi loa nā algorithm algorithm mua, ua hui pū ʻo Trazhenta me ka insulin a me kekahi ʻano lāʻau antidiabetic me kahi ʻano like ʻole o ka hana.

ʻAʻole i hoʻouna ʻia iā Trazhent

Lanakila ʻo Linagliptin no ia mau ʻano o ka maʻi maʻi.

ʻAno maʻi type 1
Hoʻokumu ʻia ka Ketoacidosis e ka maʻi maʻi,
ʻLelo a me ka lactating
Nā keiki a ʻōpio
Hypersensitivity i nā mea o ke ʻano.

Nā hopena hopena

Ma ke ala e lawe ai i ka linagliptin, hiki i nā hopena hopena ke ulu.

Nasopharyngitis (kahi maʻi ʻeha)
Nā kēkē lau
Hypersensitivity
ʻO ka pancreatitis
I ka hoʻonui ʻia o ka triglycerol (i ka wā i hui pū ʻia me ka lālani palama sulfonylurea),
Hoʻohui i nā waiwai LDL (me ka hoʻokele o ka pioglitazone),
Kau ka paona
Nā hōʻailona hypoglycemic (e kū'ē i ka mua o ke ʻano o ka papa ʻelua a me ʻekolu.

ʻO ke kū pinepine a me ka nui o nā hopena maikaʻi aʻe e hoʻomake ma hope o ka ʻai ʻana iā Trazhenta e like me ka nui o nā hanana pōʻino ma hope o ka hoʻohana ʻana i ka placebo. ʻO ka hapa pinepine, ʻo nā hopena ʻaoʻao ka hopena o ka triple complex therapy o Trazhenta me nā metformin a me nā derivatives sulfonylurea.

Hiki i ka lāʻau lapaʻau ke hōʻeha i nā pilikia koikoi, he mea nui e noʻonoʻo i kēia ke ke kaʻa ʻana i nā kaʻa a me nā ʻano paʻakikī.

Ke keu

Hāʻawi ʻia nā mea hana 120 papa (600 mg) i ka manawa. ʻAʻole i hōʻeha ʻia kekahi overdose hoʻokahi i ke kūlana olakino o nā mea hana mai kahi hui olakino olakino. Ma waena o nā maʻi maʻi, ua loaʻa ʻole nā hihia nui loa e nā helu olakino. A ʻoiai, inā i make a ʻole paha e hoʻohana i kekahi mau ʻōhua i ka manawa like, pono nā mea ʻūlū e holoi i ka ʻōpū a me ka ʻawaʻawa e kinai i ka ʻāpana ʻole o ka lāʻau, hāʻawi i nā sorbents a me nā mea ʻē aʻe e like me ke ʻano, me ka hōʻike ʻana i ke kauka.

Pehea e lawe ai i ka lāʻau

Wahi a nā ʻōkuhi no ka hoʻohana ʻana, pono e lawe ʻia ka mea papa i ka papa ʻaina (5 mg) ʻekolu mau manawa o ka lā. Inā hoʻohana ʻia ka lāʻau lapaʻau i ka mālama ʻana i ka paʻakikī me ka metformin, a laila mālama ʻia ka nui o ka hopena.

Diabetes me ka renal a i ʻole hepatic insufficiency e pono ai e hoʻoponopono he hoʻoponopono. ʻAʻole ʻokoʻa nā maʻamau maʻamau no nā poʻe maʻi o nā makahiki pākeke. I kahi senile (mai 80 mau makahiki), ʻaʻole i kuhikuhi ʻia ʻo Trazhenta ma muli o ka nele o ke kaukau ʻana i ka maʻi ma kēia ʻano makahiki.

Inā hala ka manawa no ka lawe ʻana i ka lāʻau lapaʻau, pono ʻoe e inu i kahi ʻapo i ka hiki. ʻAʻole hiki ke hoʻolōʻihi i ke ʻano. ʻAʻole pili ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau i ka manawa ʻai.

ʻO ka mana o ka trazhenti ma ka hāpai ʻana a me ka lactation

ʻAʻole i hoʻopuka ʻia nā hopena o ka hoʻohana ʻana i ka lāʻau e nā wahine hāpai. Ma kēia manawa, ua mālama ʻia nā noiʻi ʻana ma luna o nā holoholona wale nō, ʻaʻole i hōʻike ʻia nā hōʻailona o nā palaka o ka reproduction. A ʻo ka wā, i ka wā hāpai ʻana, ʻaʻole i kuhikuhi ʻia nā wāhine i ka lāʻau lapaʻau.

I nā hoʻokolohua me nā holoholona, ʻike ʻia ua hiki i ka lāʻau lapaʻau ke komo i loko o ka waiū o ka makuahine o ka wahine. No laila, i ka wā e hānai ai, ʻaʻole i hāʻawi ʻia nā wāhine iā Trazhent. Inā makemake ke kūlana o ke olakino i kēlā ʻano maʻi, ua hoʻohuli ʻia ke keiki i ka meaʻai maʻamau.

ʻAʻole i hōʻike ʻia nā hoʻokolohua ma ka hopena o ka lāʻau lapaʻau ma ka hiki ke hānai i kahi keiki. ʻAʻole i hōʻike ʻia nā ʻano hoʻokolohua like me nā holoholona ma kahi o kēia ʻaoʻao.

Hoʻohui nūhou

ʻO ka hoʻohana like ʻana o Trazhenta a me Metformin, ʻoiai inā i ʻoi aku ke kiʻekiʻe o ka palena ma mua o ke ʻano, ʻaʻole i alakaʻi i nā ʻokoʻa koʻikoʻi i loko o ka pharmacokinetics o nā lāʻau.

ʻO ka hoʻohana ʻana i ka hoʻohana ʻana o Pioglitazone ʻaʻole e loli i ka pono pharmacokinetic o nā lāʻau ʻelua.

ʻAʻole hōʻeha ka mālama loea me Glibenclamide no Trazhenta, no ka mea hope loa, ua emi iki ʻo Cmax (ma ka 14%).

Hōʻike kekahi hopena like o ka hoʻopili ʻana e nā lāʻau ʻē aʻe o ka papa sulfonylurea.

ʻO ka hui pū ʻana o ka ritonavir + linagliptin e hoʻonui nei i ka Cmax ma 3 mau manawa, ʻaʻole pono nā loli like.

ʻO nā hui pū me Rifampicin e hoʻonāukiuki i ka hōʻemi ma Cmax Trazenti. ʻO ka hapa, mālama ʻia nā hiʻohiʻona o ka lāʻau lapaʻau, akā ʻaʻole e hana ka lāʻau lapaʻau i ka 100%.

He mea weliweli e kuhikuhi iā Digoxin i ka manawa like me ka lynagliptin: ʻaʻole loli nā pharmacokinetics o nā lāʻau ʻelua.

ʻAʻole pili ʻo Trazhent i ka hiki iā Varfavin.

Hoʻomaʻamaʻa ʻia nā hoʻololi liʻiliʻi me ka hoʻohana like ʻana o ka linagliptin me ka simvastatin, akā, ʻaʻole i hoʻopōmaikaʻi ʻia ka mimetin mimetic i kāna mau hiʻohiʻona.

E kū'ē i ke kua o ka lapaʻau me Trazhenta, hiki ke hoʻohana manuahi ʻia nā maʻi o ka waha.

Nā ʻōlelo ʻokoʻa

ʻAʻole i kuhikuhi ʻia ʻo Trazent no ka maʻi maʻamau a me ka ketoacidosis, kahi hoʻohui o ka maʻi maʻi.

ʻO ka loli o nā kūlana hypoglycemic ma hope o ka mālama ʻana me ka linagliptin, i hoʻohana ʻia me ka monotherapy, i lawa i ka nui o nā hihia me ka pletebo.

Ua hōʻike ʻia nā hoʻokolohua haukapila i ʻike ʻole ʻia ka lōʻihi o ka piʻi ʻana o ka hypoglycemia i ka wā e hoʻohana ai ʻo Trezhenta i ka hui hoʻohui ʻana i ka mālama ʻana i ka hopena, no ka mea, ʻaʻole i hoʻokō ʻia ka pilikia koʻikoʻi e ka linagliptin, akā nā metformin a me nā lāʻau lapaʻau o ka pūʻulu thiazolidinedione.

E nānā pono ka makaʻala i ke kuhikuhi ʻana iā Trazhenta i ka hui pū ʻana me nā lāʻau lapaʻau sulfonylurea, ʻo ia ka mea e hoʻokau ai i ka hypoglycemia. I ka hopena koʻikoʻi, pono ia e hoʻoponopono i ka nui o nā lāʻau lapaʻau o ka hui sulfonylurea.

ʻAʻole pili ʻo Linagliptin i ka hopena o ka hoʻomohala ʻana i nā ala āpau o ka puʻuwai a me nā kīʻaha koko.

I ka hui hui, hiki ke hoʻohana ʻia ʻo Trazhent a me ke koʻikoʻi paha o ka hana renal impaired.

I nā mea maʻi o ka wā pākeke (ma mua o 70 mau makahiki), hōʻike ʻo Trezenta i hōʻike maikaʻi i ka hopena HbA1c: ʻo ka hemoglobin glycosylated mua he 7.8%, ka hopena - 7.2%.

ʻAʻole hoʻonā ka lāʻau lapaʻau i ka piʻi nui o ka pilikia cardiovascular. ʻO ka pahuhopu mua e hōʻike ana i ka neʻe a me ka manawa o ka make, hōʻeha ka naʻau, ka puʻuwai, ka hoʻomau ʻole o ka angina pectoris e koi ana i ka hoʻokipa, maʻi ma waena o nā poʻe maʻi maʻi i lawe i ka linagliptin a ʻoi aku ka hopena a ma hope o nā mea hana ma ka hui mana i loaʻa ka placebo a i nā hoʻohālikelike i nā lāʻau lapaʻau.

I kekahi mau hihia, ua hoʻāla ʻia ka hoʻohana ʻana o ka linagliptin i ka hōʻeha ʻana i ka maʻi pancreatitis.

Inā loaʻa nā hōʻailona (ʻeha hōʻeha i ka epigastrium, nā maʻi dyspeptic, nāwaliwali maʻamau), pono e oki ʻia ka lāʻau lapaʻau a nīnau aku i kāu kauka.

ʻAʻole i hoʻokele ʻia nā haʻawina e pili ana i ka mana o Trazhenta i ka hiki ke hoʻokele i nā kaʻa a me nā ʻākana paʻakikī, akā no ka hiki ʻana ke hoʻopohapula hiki, e lawe i ka lāʻau lapaʻau inā pono, me ka hopohopo kiʻekiʻe a me ke wikiwiki hoʻi me ka makaʻala.

Nā hōʻike a me ke kumu kūʻai o ka lāʻau lapaʻau

No ka lāʻau lapaʻau Trazhenta, aneʻi ke kumukūʻai mai 1500-1800 rubles no nā papa 30 no ka nui o ka nui o 5 mg. Hoʻokuʻu ʻia ka lāʻau lapaʻau kāpena.

ʻO nā hui o nā papa like o ka papa DPP-4 e pili ana iā Januvia e pili ana i ka synagliptin, Ongliz e pili ana i ka saxagliptin a me Galvus me ka vildagliptin neʻe ikaika. Hoʻopili kēia mau lāʻau i ka code ATX Level 4.

Hoʻohui ʻia kahi hopena like ʻole e nā lāʻau ʻo Sitagliptin, Alogliptin, Saksagliptin, Vildagliptin.

ʻAʻohe kūlana kūikawā no ka mālama ʻana o Trazenti i nā ʻōlelo kuhikuhi. No nā makahiki ʻekolu (e like me ka lā pau o ka manawa), mālama ʻia nā papa i ka mahana o ka lumi (a hiki i +25 mau palena) i kahi wahi pōʻeleʻele ʻole i loaʻa e nā keiki. ʻAʻole hiki ke hoʻohana ʻia nā lāʻau lapaʻau hoʻopau, pono e kiola ʻia.

ʻO ka maʻi maʻi a me nā kauka e pili ana iā Trazhent

ʻO Trazhenty ka hoʻokō koʻikoʻi i nā hui like ʻole i hōʻoia ʻia e nā haʻawina a me nā hana lapaʻau. Ua makemake nā Endocrinologists e hoʻohana i ka linagliptin e like me ka lāʻau lapaʻau mua a i ʻole ke hui pū ʻana. Me ka uluʻana i ka hypoglycemia (ka hana kino kaumaha, ka maikaʻi o ka ʻai), ma kahi o nā lāʻau lapaʻau sulfonylurea, ua kuhikuhi ʻia i Trazhent, aia nā loiloi e pili ana i ka lāʻau o ka lāʻau no ka pale ʻana i ka insulin a me ka momona. Ua loaʻa i nā maʻi he nui i ka lāʻau lapaʻau ma ke ʻano o ka mālama ʻana i nā mea paʻakikī, no laila he paʻakikī ke loiloi i kona kū pono, akā ma ka mea āpau, hauʻoli ka poʻe āpau me ka hopena.

Hoʻololi ka poʻe DPP-4, ka mea a Trazhenta, ʻaʻole wale i ka haʻi aku i nā hana antidiabetic, akā, i ka piʻi ʻana o ka palekana, no ka mea ʻaʻole lākou e hoʻonāukiuki i ka hopena hypoglycemic, ʻaʻole i hāʻawi i ka waiwai momona, a ʻaʻole i hoʻonui i ka maikaʻi ʻole. I kēia manawa, ua manaʻo ʻia kēia papa o nā lāʻau lapaʻau kekahi o nā mea i hoʻohiki mua ʻia no ka mālama ʻana i ka maʻi type 2.